Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Tremelimumab in HR+/HER2- Breast Cancer
NCT03132467Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2017
- Primary completion
- Jan 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab and tremelimumab in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Feasibility of Enrolling 15 Patients Within 2 Years and Safety and Tolerability of Tremelimumab Plus Durvalumab at 2 months. Started Jun 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03132467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132467.